CONNECT WITH US
HealthTech

HealthTech

Gilead CAR-T on partial clinical hold; Agios' PDUFA date pushed back

Endpoints News logo

Published on

Add as a preferred source on Google
Gilead CAR-T on partial clinical hold; Agios' PDUFA date pushed back

Plus news about Acu­men, Bris­tol My­ers Squibb, Re­gen­eron, Aer Ther­a­peu­tics and Hemay Phar­ma­ceu­ti­cal.

Gilead paus­es CAR-T af­ter ICANS: Af­ter sev­er­al cas­es of the neu­ro­log­i­cal con­di­tion …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Ono's five fail­ures; Lenz and Mol­e­c­u­lar Part­ners to lay off staff October 29, 2026

Out­pace ends an ovar­i­an can­cer tri­al; In­cyte da­ta im­press­es at ES­MO October 27, 2026

As­pen and Bam­busa tar­get $135M IPOs; As­traZeneca vs. Take­da in gas­tric can­cer AD­Cs October 26, 2026

Af­ter Be Bio shut­down, its CEO heads to Or­bis; Enan­ta's long­time chief Jay Lu­ly to re­tire

As­traZeneca says re­org could mean R&D cuts and tri­als shift­ed to emerg­ing mar­kets

Sanofi has no plans for a 'ma­jor' over­haul as Dupix­en­t's patent cliff looms

Se­tara gets $90M to con­tin­ue rare dis­ease pipeline spun out of Jaz­z's Ac­tio deal



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.